triazoles has been researched along with Osteolysis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guise, TA; Harhash, AA; John, SK; Kozlow, WM; Marks, AR; Mohammad, KS; Murthy, S; Niewolna, M; Regan, JN; She, Y; Waning, DL; Wright, LE | 1 |
| Alsamad, IA; Botterel, F; Coste, A; Papon, JF; Pruliere-Escabasse, V; Toussain, G; Zerah-Lancner, F | 1 |
| Arechavala, A; Bianchi, MH; López Daneri, G; Negroni, R; Robles, AM; Santiso, G | 1 |
3 other study(ies) available for triazoles and Osteolysis
| Article | Year |
|---|---|
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Estradiol; Female; Humans; Imidazoles; Letrozole; Mice, Inbred BALB C; Mice, Nude; Muscle Strength; Muscle Weakness; Muscle, Skeletal; Nitriles; Osteolysis; Ovariectomy; Receptors, Estrogen; Time Factors; Triazoles; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
Sinus fungal balls: characteristics and management in patients with host factors for invasive infection.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Endoscopy; Female; Humans; Male; Middle Aged; Mycoses; Osteolysis; Paranasal Sinus Diseases; Retrospective Studies; Risk Factors; Triazoles | 2012 |
[Clinical cases in medical mycology. Case no. 21].
Topics: Amphotericin B; Antifungal Agents; Dermatomycoses; Drug Resistance, Fungal; Endophthalmitis; Exophiala; Female; Fungemia; Humans; Itraconazole; Middle Aged; Mycoses; Opportunistic Infections; Osteolysis; Pregnancy; Pregnancy Complications, Infectious; Pyrimidines; Recurrence; Th2 Cells; Triazoles; Voriconazole | 2006 |